NCT05102071撤回不适用
Clinical and Economic Impact of 2nd Line Initiation of Empagliflozin After Metformin, as Compared to 2nd Line Initiation of Sulfonylurea After Metformin in Patients With Type 2 Diabetes and Cardiovascular Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Occurrence of first hospitalization for congestive heart failure (HHF)
研究概览
简要总结
Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization for heart failure), and healthcare cost, and resource utilization, among patients on empagliflozin as an add-on therapy to metformin versus patients on sulfonylureas as an add-on therapy to metformin in patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment with a sulfonylurea
as add-on therapy with metformin
干预措施: metformin (Drug)
Treatment with empagliflozin
as add-on therapy with metformin
干预措施: empagliflozin (Drug)
Treatment with empagliflozin
as add-on therapy with metformin
干预措施: metformin (Drug)
Treatment with a sulfonylurea
as add-on therapy with metformin
干预措施: sulfonylurea (Drug)
结局指标
主要结局
Occurrence of first hospitalization for congestive heart failure (HHF)
时间窗: up to 5 years and 3 months
次要结局
- Hospitalizations(up to 5 years and 3 months)
- Emergency department (ED) visits(up to 5 years and 3 months)
- Number of filled drugs(up to 5 years and 3 months)
- Outpatient visits(up to 5 years and 3 months)
- All cause cost(up to 5 years and 3 months)
- Length of stay(up to 5 years and 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluation of Cardiovascular Health Outcomes Among SurvivorsCardiovascular RiskCancerNCT01003574St. Jude Children's Research Hospital509
终止
不适用
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)Graft Versus Host DiseaseNCT02151539Vanderbilt-Ingram Cancer Center19
已完成
不适用
Cost-utility Analysis, Cost-effectiveness Analysis, Budget Impact AnalysisPeripheral Arterial DiseaseNCT04283565University Hospital, Tours614
已完成
不适用
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic MedicationsRheumatic DiseasesMyocardial IschemiaNCT02694185VA Office of Research and Development5,269
已完成
不适用
Impact of Guidelines on Cardiovascular and Economic Outcomes With Focus on Lipid Lowering DrugsAcute Myocardial InfarctionNCT02929550Karolinska Institutet5,304